These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26302232)

  • 21. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway.
    Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B
    J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
    Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
    Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
    Liu F; Wu X; Qian Y; Jiang X; Wang Y; Gao J
    Cell Death Dis; 2020 Jun; 11(6):427. PubMed ID: 32513919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
    Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
    Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
    Sun TM; Du JZ; Yao YD; Mao CQ; Dou S; Huang SY; Zhang PZ; Leong KW; Song EW; Wang J
    ACS Nano; 2011 Feb; 5(2):1483-94. PubMed ID: 21204585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
    Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
    Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
    Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.
    Sun R; Liu Y; Li SY; Shen S; Du XJ; Xu CF; Cao ZT; Bao Y; Zhu YH; Li YP; Yang XZ; Wang J
    Biomaterials; 2015 Jan; 37():405-14. PubMed ID: 25453968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma.
    Wang XQ; Zhang W; Lui EL; Zhu Y; Lu P; Yu X; Sun J; Yang S; Poon RT; Fan ST
    Int J Cancer; 2012 Aug; 131(3):E163-72. PubMed ID: 22052196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of mitogen-activated protein kinase inhibitor for hepatocellular carcinoma stem cell therapy.
    Liu Y; Wang X; Sun CY; Wang J
    ACS Appl Mater Interfaces; 2015 Jan; 7(1):1012-20. PubMed ID: 25522342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
    Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
    J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines.
    Yang J; Gong Y; Sontag DP; Corbin I; Minuk GY
    Mol Biol Rep; 2018 Oct; 45(5):1023-1036. PubMed ID: 30069818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
    Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
    Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
    Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
    J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
    Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
    Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.
    Jiang J; Chen H; Yu C; Zhang Y; Chen M; Tian S; Sun C
    Nanomedicine (Lond); 2015 Jul; 10(12):1863-79. PubMed ID: 26139123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.